Edition:
India

Mylan NV (MYL.OQ)

MYL.OQ on NASDAQ Stock Exchange Global Select Market

14.78USD
21 Sep 2020
Change (% chg)

$0.00 (-0.00%)
Prev Close
$14.78
Open
$15.43
Day's High
$15.46
Day's Low
$14.61
Volume
3,036,489
Avg. Vol
1,970,295
52-wk High
$23.11
52-wk Low
$12.76

Select another date:

Tue, Sep 8 2020

UPDATE 1-S.Africa's Aspen sells thrombosis drug business to Mylan, shares jump

JOHANNESBURG, Sept 8 South African drugmaker Aspen Pharmacare has agreed to sell the rights to its European thrombosis business to U.S. pharmaceutical company Mylan for almost 642 million euros ($759 million), sending its shares up 7% on Tuesday.

UPDATE 3-Mylan tightens revenue estimates on COVID-19 pressure; shares fall

Aug 6 Mylan NV on Thursday lowered the top-end of its full-year sales estimate, saying a recovery of demand for its non-coronavirus related medicines would take until at least the end of the year, sending its shares down as much as 3.5%.

Mylan posts quarterly profit compared to year-earlier loss

Aug 6 Mylan NV reported a second-quarter profit on Thursday, helped in part by strong sales of its newly launched products such as asthma drug Wixela.

Mylan gets Indian regulatory approval for tuberculosis drug

BENGALURU Drugmaker Mylan NV said on Wednesday it has received Indian regulatory approval to make tuberculosis treatment pretomanid available in a country that accounts for a quarter of the world's cases.

BRIEF-Mylan And Fujifilm Kyowa Kirin Biologics Announce U.S. FDA Approval Of Hulio (Adalimumab-Fkjp)

* MYLAN AND FUJIFILM KYOWA KIRIN BIOLOGICS ANNOUNCE U.S. FDA APPROVAL OF HULIO® (ADALIMUMAB-FKJP)

BRIEF-Mylan Initiates Voluntary Nationwide Recall Of One Lot Of Daptomycin For Injection

* MYLAN INITIATES VOLUNTARY NATIONWIDE RECALL OF ONE LOT OF DAPTOMYCIN FOR INJECTION, DUE TO THE PRESENCE OF PARTICULATE

Mylan prices its generic remdesivir in India at $64 per 100 mg vial

BENGALURU Mylan NV said on Monday it would launch a generic version of Gilead Sciences Inc's COVID-19 antiviral remdesivir in India at 4,800 rupees ($64.31), about 80% below the price tag on the drug for wealthy nations.

Mylan prices its generic remdesivir in India at $64 per 100 mg vial

BENGALURU Mylan NV said on Monday it would launch a generic version of Gilead Sciences Inc's COVID-19 antiviral remdesivir in India at 4,800 rupees ($64.31), about 80% below the price tag on the drug for wealthy nations.

UPDATE 1-Mylan prices its generic remdesivir in India at $64 per 100 mg vial

BENGALURU, July 6 Mylan NV said on Monday it would launch a generic version of Gilead Sciences Inc's COVID-19 antiviral remdesivir in India at 4,800 rupees ($64.31), about 80% below the price tag on the drug for wealthy nations.

Mylan to launch generic remdesivir version in India at $64 per 100 mg vial

BENGALURU, July 6 Drugmaker Mylan NV said on Monday it would launch its generic version of Gilead Sciences Inc's COVID-19 treatment remdesivir in India this month at 4,800 rupees ($64.31) per 100 mg vial, as infections surge in the world's third worst-hit country.

Select another date: